{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:25:14Z","timestamp":1769750714164,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40744-023-00552-2","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:01:47Z","timestamp":1685019707000},"page":"951-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Benefits of Autoantibody Enrichment in Early Rheumatoid\u00a0Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials"],"prefix":"10.1007","volume":"10","author":[{"given":"Kaleb","family":"Michaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Khaychuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"552_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12: 680043. https:\/\/doi.org\/10.3389\/fphar.2021.680043.","journal-title":"Front Pharmacol."},{"issue":"13","key":"552_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","journal-title":"JAMA"},{"issue":"9","key":"552_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","volume":"32","author":"T Uhlig","year":"2014","unstructured":"Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014;32(9):841\u201351. https:\/\/doi.org\/10.1007\/s40273-014-0174-6.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"552_CR4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","volume":"62","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955\u20132007. Arthritis Rheum. 2010;62(6):1576\u201382. https:\/\/doi.org\/10.1002\/art.27425.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"552_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2009.12.009","volume":"35","author":"GJ Tobon","year":"2010","unstructured":"Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun. 2010;35(1):10\u20134. https:\/\/doi.org\/10.1016\/j.jaut.2009.12.009.","journal-title":"J Autoimmun"},{"issue":"4","key":"552_CR6","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"8","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;8(4):18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"552_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"552_CR8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","volume":"35","author":"W Katchamart","year":"2015","unstructured":"Katchamart W, Koolvisoot A, Aromdee E, et al. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int. 2015;35(10):1693\u20139. https:\/\/doi.org\/10.1007\/s00296-015-3271-8.","journal-title":"Rheumatol Int"},{"issue":"2","key":"552_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.autrev.2012.05.007","volume":"12","author":"LA Trouw","year":"2012","unstructured":"Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12(2):318\u201322. https:\/\/doi.org\/10.1016\/j.autrev.2012.05.007.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"552_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.autrev.2010.08.009","volume":"10","author":"AS Wiik","year":"2010","unstructured":"Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev. 2010;10(2):90\u20133. https:\/\/doi.org\/10.1016\/j.autrev.2010.08.009.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"552_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933\u20138. https:\/\/doi.org\/10.1002\/art.30233.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"552_CR12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/ard.2008.088070","volume":"67","author":"K Visser","year":"2008","unstructured":"Visser K, Verpoort KN, van Dongen H, et al. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis. 2008;67(8):1194\u20135. https:\/\/doi.org\/10.1136\/ard.2008.088070.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"552_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","volume":"23","author":"W Rigby","year":"2021","unstructured":"Rigby W, Buckner JH, Louis Bridges S Jr, et al. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res Ther. 2021;23(1):245. https:\/\/doi.org\/10.1186\/s13075-021-02607-7.","journal-title":"Arthritis Res Ther."},{"key":"552_CR14","doi-asserted-by":"crossref","unstructured":"Huizinga TW, Connolly SE, Johnsen A, et al. Effect of anti-cyclic citrullinated peptide 2 immunoglobulin M serostatus on efficacy outcomes following treatment with abatacept plus methotrexate. 2015 ACR\/ARHP Annual Meeting 2015.","DOI":"10.1136\/annrheumdis-2015-eular.1983"},{"issue":"4","key":"552_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75(4):709\u201314. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207942.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"552_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.170007","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Litman HJ, Connolly SE, et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US national observational study. J Rheumatol. 2018;45(1):32\u20139. https:\/\/doi.org\/10.3899\/jrheum.170007.","journal-title":"J Rheumatol"},{"issue":"12","key":"552_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870\u20137. https:\/\/doi.org\/10.1136\/ard.2008.101121.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"552_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28\u201338. https:\/\/doi.org\/10.1002\/art.37711.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"552_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19\u201326. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206106.","journal-title":"Ann Rheum Dis"},{"key":"552_CR20","unstructured":"Bristol-Myers Squibb Company. Highlights of Prescribing Information ORENCIA (abatacept) 2021. https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf. Accessed 13 Mar 2023."},{"issue":"3","key":"552_CR21","first-page":"455","volume":"38","author":"E Alemao","year":"2020","unstructured":"Alemao E, Postema R, Elbez Y, et al. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2020;38(3):455\u201366.","journal-title":"Clin Exp Rheumatol."},{"issue":"2","key":"552_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier DS, Chatzidionysiou K, Mongin D, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 2021;60(2):820\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keaa393.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"552_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2478\/rir-2021-0003","volume":"2","author":"W Sung","year":"2021","unstructured":"Sung W, Tsai W. Rethink about the role of rheumatoid factor and anti-citrullinated protein antibody in rheumatoid arthritis. Rheumatol Immunol Res. 2021;2(1):19\u201325.","journal-title":"Rheumatol Immunol Res"},{"issue":"2","key":"552_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40744-021-00404-x","volume":"9","author":"O Jabado","year":"2022","unstructured":"Jabado O, Maldonado MA, Schiff M, et al. Differential changes in ACPA fine specificity and gene expression in a randomized trial of abatacept and adalimumab in rheumatoid arthritis. Rheumatol Therapy. 2022;9(2):391\u2013409.","journal-title":"Rheumatol Therapy"},{"key":"552_CR25","volume-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients\u2014a longitudinal analysis. Seminars in arthritis and rheumatism","year":"2017","unstructured":"Wunderlich C, Oliviera I, Figueiredo CP, et al editors. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients\u2014a longitudinal analysis. Seminars in arthritis and rheumatism. Amsterdam: Elsevier; 2017."},{"issue":"7","key":"552_CR26","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1136\/ard.2009.122739","volume":"69","author":"BJ Miriovsky","year":"2010","unstructured":"Miriovsky BJ, Michaud K, Thiele GM, et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1292\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00552-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T13:04:39Z","timestamp":1688648679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00552-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00552-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}